[Management of hemorrhagic XXXX with hyperbaric @entity26 therapy].

@entity1 @entity1204 @entity263 @entity1494 @entity5 @entity26 @entity150 @entity2335
INTRODUCTION AND OBJECTIVES: @entity2335 ( @entity2335 ) after pelvic radiotherapy occurs in 2-8% of @entity1 . A variety of treatments have been described, most of them with uncertain results. We assessed the efficacy of hyperbaric @entity26 therapy (HBOT) in @entity2335 cases. @entity1 AND METHODS: retrospective analysis of @entity1 with @entity2335 after pelvic radiotherapy receiving HBOT at our center between January 2002 and January 2010. Our protocol included 40 sessions of HBOT in a multiplace hyperbaric chamber with 90minutes of 100% @entity26 breathing at 2.2 atm. Success was evaluated in terms of total or partial stop of @entity1494 . Telephone follow-up was updated at the time of submission in all cases. RESULTS: twenty-five @entity1 were treated (21 male, 4 female); the mean age was 66.7 years. Twenty @entity1 were irradiated for @entity263 and one for @entity150 . Three @entity1 had @entity5 and one @entity1204 . In all cases previous conservative treatment had failed and HBOT was considered only after other measures failed. All the @entity1 responded to HBOT and none recurred after end of treatment at a mean follow-up of 21.2 months. There were no serious complications. CONCLUSION: HBOT is a highly effective and safe, non-invasive therapy for @entity2335 secondary to pelvic radiation; it should be considered as first line alternative in these difficult cases.
